ZMYND11

Across TCGA pan-cancer cohorts, ZMYND11 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZMYND11 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZMYND11 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZMYND11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, CESC, and STAD are the cancer types where ZMYND11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.938	0.612	.020	20	view →
CESC	DFS	Median	All	0.224	0.742	.010	12	view →
STAD	DFS	Median	II,III,IV	1.000	0.376	.024	12	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZMYND11–UCEC (DFS)

Open the UCEC breakdown →